Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489698 | 0.93 | NSD2 (0.49) | L3MBTL1POLBCYP19A1FABP4NSD2 | |
| SCHEMBL4482026 | 0.87 | CA12 (0.56) | L3MBTL1CYP19A1FABP4NSD2MEN1 | |
| SCHEMBL4483280 | 0.87 | CYP19A1 (0.50) | L3MBTL1CYP19A1FABP4NSD2MEN1 | |
| SCHEMBL4483089 | 0.86 | CYP2C19 (0.65) | CYP19A1FABP4MEN1GAAKMT2A | |
| SCHEMBL4487088 | 0.84 | MEN1 (0.57) | L3MBTL1CYP19A1FABP4NSD2MEN1 | |
| SCHEMBL4483934 | 0.83 | MEN1 (0.52) | L3MBTL1CYP19A1FABP4NSD2MEN1 | |
| SCHEMBL4492967 | 0.82 | KMT2A (0.51) | POLBMEN1GAAKMT2AESR1 | |
| SCHEMBL4473385 | 0.82 | MEN1 (0.50) | L3MBTL1CYP19A1FABP4NSD2MEN1 | |
| SCHEMBL4472800 | 0.81 | POLB (0.57) | L3MBTL1POLBMEN1GAAKMT2A | |
| SCHEMBL4477941 | 0.81 | MEN1 (0.49) | L3MBTL1CYP19A1FABP4NSD2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | claimed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | claimed |
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215645-A1 | Amide derivatives | OGG1, HDAC1, BCL2A1 | L3MBTL1 1618/4885POLB 296/4885CYP19A1 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.